The National Health Surveillance Agency (Anvisa), Brazil’s regulatory body, approved this Wednesday emergency use of Janssen’s single dose vaccine against Covid-19, European subsidiary of Johnson & Johnson.
The laboratory, that had already obtained from Anvisa the certificates of good manufacturing practices of the immunizer, filed for emergency use on March 24, receiving approval from the Brazilian regulatory agency.
The Ministry of Health of Brazil had already closed a contract for the acquisition of 38 million doses of Janssen’s single-dose antidote, to be delivered in the 3rd and 4th semester of this year, and with the unit value of 10 dollars (8.53 euros, in the current exchange rate) per dose.
In the South American country, vaccines from Pfizer and AstraZeneca / Oxford have already obtained the definitive registration for application in the Brazilian population, and CoronaVac, developed by Sinovac, but in production in Brazil by the Butantan Institute, received authorization to use emergency. The Janssen immunizer involved clinical tests carried out in different countries, including Brazil.
PUB • CONTINUE READING NEXT
Brazil, which is going through its most critical moment in the pandemic, totals 317,646 deaths and 12,658,109 diagnoses of infection since the first case was registered in the country, about 13 months ago.
The Covid-19 pandemic caused at least 2,805,004 deaths worldwide, resulting from more than 128.1 million cases of infection, according to a report made by the French agency AFP.
Get the latest news delivered to your inbox
Follow us on social media networks